ERAS vs. VERV, BDTX, LYEL, NUVB, RLAY, GLPG, AGIO, PTGX, ZLAB, and KROS
Should you be buying Erasca stock or one of its competitors? The main competitors of Erasca include Verve Therapeutics (VERV), Black Diamond Therapeutics (BDTX), Lyell Immunopharma (LYEL), Nuvation Bio (NUVB), Relay Therapeutics (RLAY), Galapagos (GLPG), Agios Pharmaceuticals (AGIO), Protagonist Therapeutics (PTGX), Zai Lab (ZLAB), and Keros Therapeutics (KROS). These companies are all part of the "medical" sector.
Erasca (NASDAQ:ERAS) and Verve Therapeutics (NASDAQ:VERV) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, valuation, earnings, dividends, community ranking, analyst recommendations and risk.
Erasca and Verve Therapeutics both received 18 outperform votes by MarketBeat users. However, 64.29% of users gave Erasca an outperform vote while only 46.15% of users gave Verve Therapeutics an outperform vote.
Erasca currently has a consensus price target of $7.33, indicating a potential upside of 188.71%. Verve Therapeutics has a consensus price target of $33.00, indicating a potential upside of 525.00%. Given Verve Therapeutics' higher possible upside, analysts plainly believe Verve Therapeutics is more favorable than Erasca.
In the previous week, Erasca had 19 more articles in the media than Verve Therapeutics. MarketBeat recorded 21 mentions for Erasca and 2 mentions for Verve Therapeutics. Erasca's average media sentiment score of 0.96 beat Verve Therapeutics' score of 0.62 indicating that Erasca is being referred to more favorably in the media.
Erasca has a beta of 1.06, meaning that its share price is 6% more volatile than the S&P 500. Comparatively, Verve Therapeutics has a beta of 1.94, meaning that its share price is 94% more volatile than the S&P 500.
67.8% of Erasca shares are held by institutional investors. Comparatively, 97.1% of Verve Therapeutics shares are held by institutional investors. 21.5% of Erasca shares are held by company insiders. Comparatively, 19.3% of Verve Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Erasca has a net margin of 0.00% compared to Verve Therapeutics' net margin of -1,226.51%. Verve Therapeutics' return on equity of -37.35% beat Erasca's return on equity.
Erasca has higher earnings, but lower revenue than Verve Therapeutics. Erasca is trading at a lower price-to-earnings ratio than Verve Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Erasca and Verve Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.
Get Erasca News Delivered to You Automatically
Sign up to receive the latest news and ratings for ERAS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ERAS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
